METHOD FOR THE TREATMENT OF RESPIRATORY TUBERCULOSIS IN CHILDREN AND ADOLESCENTS IN THE EVENT OF ADVERSE REACTIONS Russian patent published in 2022 - IPC A61K31/573 A61P31/06 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to phthisiology, and can be used to accompany chemotherapy in the treatment of respiratory tuberculosis in children and adolescents with allergic, toxic-allergic and toxic side reactions. Prednisolone is prescribed when chemotherapy is restored to children aged 3 to 12 years at a dose of 0.5 mg/kg per day, aged 13 to 17 years 0.25 mg/kg per day with a maximum daily dose of 20 mg until the level of laboratory parameters normalizes transaminases, pancreatic amylase and/or hemoglobin, leukocytes, eosinophils and platelets. Then the dose of prednisolone is reduced by 1.25 mg every three days with monitoring of laboratory parameters after each dose reduction until the drug is completely discontinued. At the same time, if during the period of reducing the dose of prednisolone again there is a deviation of laboratory parameters from normal values, the dose of prednisolone is increased by 1.25 mg and does not decrease for the entire period of anti-tuberculosis chemotherapy, while the abolition of prednisolone is carried out after completion of the course of chemotherapy.

EFFECT: method makes it possible to increase the efficiency of treatment of respiratory tuberculosis in children and adolescents with the repeated development of adverse reactions during the restoration of chemotherapy and, on this basis, to expand the arsenal of technical means used in the treatment of respiratory tuberculosis in children and adolescents due to a combination of techniques of the claimed invention.

1 cl